Psychiatry · Year 3 · from Psychiatry

Case 3: Mood Stabilizer Pharmacology - Lithium

Patient Demographics

  • Age: 45 years old
  • Sex: Male
  • Occupation: Sales manager

Chief Complaint

"I think I'm stable now, but I want to make sure I understand my medication."

History of Present Illness

The patient is a 45-year-old man with a 15-year history of Bipolar I Disorder, currently stable on lithium 900 mg daily (lithium level 0.8 mEq/L). He is here for routine follow-up and medication education. He has had 4 manic episodes and 6 depressive episodes over the years, with his last episode (depression) 18 months ago.

He has been on lithium for 10 years with good response - his manic episodes have been completely prevented, and depressive episodes have been less frequent and less severe. He has tried valproate and lamotrigine in the past with less efficacy.

He is interested in better understanding his medication, particularly why he needs regular blood tests and what symptoms to watch for.

Current Medications

  • Lithium 900 mg at bedtime (level 0.8 mEq/L)
  • No other psychiatric medications

Medical History

  • Hypothyroidism (developed on lithium, on levothyroxine)
  • Mild chronic kidney disease (eGFR 62, attributed to long-term lithium)

Teaching Points: Lithium Pharmacology

Mechanism of Action (Incompletely Understood):

  • Modulates intracellular signaling cascades
  • Inhibits glycogen synthase kinase-3 beta (GSK-3β)
  • Inhibits inositol monophosphatase
  • Neuroprotective effects (increases BDNF, gray matter volume)
  • Unique anti-suicidal effect (unrelated to mood stabilization)

Pharmacokinetics:

Absorption:

  • Well absorbed orally
  • Peak levels in 1-2 hours (immediate release)
  • Extended release: Peak 4-5 hours

Distribution:

  • Not protein bound
  • Distributes in total body water
  • Volume of distribution: 0.7-1.0 L/kg

Metabolism:

  • NOT metabolized
  • No hepatic involvement (unique among psych meds)
  • Eliminated unchanged by kidneys

Elimination:

  • Half-life: 18-24 hours
  • Steady state: 5-7 days
  • 95% renal excretion
  • Reabsorbed in proximal tubule (competes with sodium)

Therapeutic Range:

  • Acute mania: 0.8-1.2 mEq/L
  • Maintenance: 0.6-1.0 mEq/L
  • Toxicity begins: >1.5 mEq/L
  • NARROW THERAPEUTIC INDEX

Monitoring Requirements

Lithium Levels:

  • Trough level (12 hours post-dose, before morning dose)
  • At initiation: Every 5-7 days until stable
  • Stable patient: Every 3-6 months
  • After dose change: 5-7 days post-change
  • If any symptoms of toxicity
  • After illness, dehydration, medication changes

Renal Function:

  • Baseline BUN, creatinine, eGFR
  • Every 6-12 months thereafter
  • Lithium can cause interstitial nephritis, reduced GFR over time
  • This patient: eGFR 62 - mild CKD, continue monitoring closely

Thyroid Function:

  • Baseline TSH
  • Every 6-12 months
  • Lithium inhibits thyroid hormone release
  • 25-30% develop hypothyroidism (treat with levothyroxine, can continue lithium)
  • This patient: On levothyroxine for lithium-induced hypothyroidism

Other Monitoring:

  • Calcium (lithium can cause hyperparathyroidism)
  • ECG if cardiac history (can affect sinus node)
  • Weight (some weight gain common)

Drug Interactions

Medications that INCREASE lithium levels (toxicity risk):

  • NSAIDs (ibuprofen, naproxen) - reduce renal clearance
  • ACE inhibitors, ARBs - reduce renal clearance
  • Thiazide diuretics - reduce sodium, increase lithium reabsorption
  • Dehydration/volume depletion - concentrates lithium

Medications that DECREASE lithium levels:

  • Caffeine (mild)
  • Theophylline
  • Sodium loading
  • Osmotic diuretics

Patient Instructions:

  • Stay well-hydrated (especially in heat, with exercise)
  • Avoid NSAIDs - use acetaminophen instead
  • Inform all providers you take lithium before starting new medications
  • Maintain consistent sodium intake

Lithium Toxicity

Signs of Toxicity (level >1.5 mEq/L):

Mild (1.5-2.0 mEq/L):

  • Coarse tremor (vs. fine tremor at therapeutic levels)
  • Nausea, vomiting, diarrhea
  • Confusion, lethargy

Moderate (2.0-2.5 mEq/L):

  • Ataxia
  • Dysarthria
  • Myoclonus
  • Increased confusion

Severe (>2.5 mEq/L):

  • Seizures
  • Cardiac arrhythmias
  • Coma
  • Death

When to Seek Emergency Care:

  • Severe diarrhea or vomiting (dehydration risk)
  • Febrile illness with reduced fluid intake
  • Confusion, ataxia, severe tremor
  • Starting new medication that interacts
  • Any concern for toxicity

Treatment of Toxicity:

  • Hold lithium
  • IV fluids for hydration
  • Hemodialysis for severe toxicity

This Patient's Plan

Current Status:

  • Stable on lithium 900 mg, level 0.8 mEq/L
  • Hypothyroidism managed
  • Mild CKD - monitor closely

Ongoing Monitoring:

  • Lithium level every 3 months (given CKD)
  • eGFR every 6 months
  • TSH every 6 months
  • Annual calcium

Patient Education Provided:

  • Signs of toxicity
  • Drug interactions (especially NSAIDs, ACE inhibitors)
  • Importance of hydration
  • When to seek emergency care

Follow-up: 3 months


Image Attribution

Image: Diagram showing mechanisms of action of major psychotropic drug classes at the synaptic level, including serotonin reuptake inhibition, dopamine receptor interactions, and GABA modulation. Source: Wikimedia Commons. Used for educational purposes under Creative Commons license.

All cases for this lecture as Markdown